JP2023535576A5 - - Google Patents
Info
- Publication number
- JP2023535576A5 JP2023535576A5 JP2023504517A JP2023504517A JP2023535576A5 JP 2023535576 A5 JP2023535576 A5 JP 2023535576A5 JP 2023504517 A JP2023504517 A JP 2023504517A JP 2023504517 A JP2023504517 A JP 2023504517A JP 2023535576 A5 JP2023535576 A5 JP 2023535576A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- eef1a2
- polynucleotide sequence
- functional variant
- pagh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055775P | 2020-07-23 | 2020-07-23 | |
| US63/055,775 | 2020-07-23 | ||
| PCT/EP2021/070455 WO2022018171A1 (en) | 2020-07-23 | 2021-07-21 | GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535576A JP2023535576A (ja) | 2023-08-18 |
| JP2023535576A5 true JP2023535576A5 (enExample) | 2024-07-30 |
Family
ID=71786970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504517A Pending JP2023535576A (ja) | 2020-07-23 | 2021-07-21 | ｅＥＦ１Ａ２の遺伝子治療ベクターおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230330265A1 (enExample) |
| EP (1) | EP4185332A1 (enExample) |
| JP (1) | JP2023535576A (enExample) |
| KR (1) | KR20230039669A (enExample) |
| CN (1) | CN116171325A (enExample) |
| AU (1) | AU2021312320A1 (enExample) |
| CA (1) | CA3186700A1 (enExample) |
| IL (1) | IL299955A (enExample) |
| MX (1) | MX2023000995A (enExample) |
| WO (2) | WO2022017630A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE055862T2 (hu) | 2016-04-20 | 2021-12-28 | Centro De Investig Energeticas | Készítmények és eljárások PKLR fokozott génexpressziójára |
| SG11202002263TA (en) | 2017-10-16 | 2020-04-29 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency |
| WO2019200167A1 (en) | 2018-04-11 | 2019-10-17 | Rocket Pharmaceuticals, Ltd. | Compositions and methods for stem cell transplant |
| MX2020011386A (es) | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| KR20230043869A (ko) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법 |
| WO2026006785A2 (en) * | 2024-06-28 | 2026-01-02 | Adverum Biotechnologies, Inc. | Melanopsin variants for vision restoration |
| WO2026044087A1 (en) | 2024-08-21 | 2026-02-26 | Shape Therapeutics Inc. | Increased cellular stability for aav production |
| WO2026073032A1 (en) | 2024-09-27 | 2026-04-02 | Shape Therapeutics Inc. | Constructs for improved aav production |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
| US7056502B2 (en) | 2000-04-28 | 2006-06-06 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| US7122350B2 (en) * | 2003-12-12 | 2006-10-17 | Zymogenetics, Inc. | Methods for enhancing expression of recombinant proteins |
| EP2176283B1 (en) | 2007-07-14 | 2016-11-02 | University of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| JP2013523776A (ja) | 2010-04-02 | 2013-06-17 | セレジーン インコーポレイテッド | パーキンソン病および脳のドーパミン作動性ニューロンのその他の障害を処置する方法 |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| LT3137497T (lt) | 2014-05-02 | 2021-07-26 | Genzyme Corporation | Aav vektoriai, skirti tinklainės ir cns genų terapijai |
| EP3285788B1 (en) * | 2015-04-23 | 2024-12-18 | University of Massachusetts | Modulation of aav vector transgene expression |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
| KR102423442B1 (ko) | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| KR102918544B1 (ko) * | 2018-07-12 | 2026-01-27 | 로켓 파마슈티컬스, 리미티드 | 다논병을 치료하기 위한 유전자 요법 벡터 |
| CA3120923A1 (en) * | 2018-11-26 | 2020-06-04 | Universitat Autonoma De Barcelona | Fibroblast growth factor 21 (fgf21) gene therapy |
-
2020
- 2020-07-24 WO PCT/EP2020/071028 patent/WO2022017630A1/en not_active Ceased
-
2021
- 2021-07-21 CA CA3186700A patent/CA3186700A1/en active Pending
- 2021-07-21 MX MX2023000995A patent/MX2023000995A/es unknown
- 2021-07-21 JP JP2023504517A patent/JP2023535576A/ja active Pending
- 2021-07-21 KR KR1020237003445A patent/KR20230039669A/ko active Pending
- 2021-07-21 US US18/017,502 patent/US20230330265A1/en active Pending
- 2021-07-21 IL IL299955A patent/IL299955A/en unknown
- 2021-07-21 WO PCT/EP2021/070455 patent/WO2022018171A1/en not_active Ceased
- 2021-07-21 AU AU2021312320A patent/AU2021312320A1/en active Pending
- 2021-07-21 CN CN202180056421.4A patent/CN116171325A/zh active Pending
- 2021-07-21 EP EP21755896.4A patent/EP4185332A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535576A5 (enExample) | ||
| CN106488984B (zh) | 一种治疗周围神经病变以及运动神经元疾病的方法 | |
| JP2023088902A5 (enExample) | ||
| JP2025179046A5 (enExample) | ||
| JP2022500066A5 (enExample) | ||
| JP2022535749A5 (enExample) | ||
| IL278213B1 (en) | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) | |
| JP2023536902A5 (enExample) | ||
| JP2023524291A5 (enExample) | ||
| JP2022501060A5 (enExample) | ||
| JP2021523718A5 (enExample) | ||
| JP2022523679A5 (enExample) | ||
| JP2021533805A5 (enExample) | ||
| JP2022531861A5 (enExample) | ||
| JP2023535956A5 (enExample) | ||
| JP2023534037A5 (enExample) | ||
| JP2024546103A5 (enExample) | ||
| JP2024504611A5 (enExample) | ||
| WO2021081280A1 (en) | Adeno-associated virus vectors based gene therapy for hereditary angioedema | |
| JP2024545183A5 (enExample) | ||
| JP2024528540A5 (enExample) | ||
| JP2024539123A5 (enExample) | ||
| JP2022536338A5 (enExample) | ||
| CN113574176A (zh) | 腺相关病毒对cln6多核苷酸的递送 | |
| JP2022525848A5 (enExample) |